88
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Patenting a drug repurposing program as a shield for staying in control

      Published
      conference-abstract
        1 ,
      RExPO24 Conference
      REPO4EU
      RExPO24
      3-5 July 2024
      Drug repurposing, therapeutic application, clinical trial, pharmaceutical legislation, patenting
      Bookmark

            Abstract

            Drug repurposing programs embody the potential to extend therapeutic application of an existing drug molecule to a novel indication, to aid patients with an unmet medical need. Developing an existing drug for a new indication may be a faster route to the clinic. This may likely be a less cost-intensive approach, too, due to potentially suitability of existing clinical trial data in the registration process. Here, regularly faster development and at lower cost compared to the R&D program for a new medicinal molecule. A series of aspects is relevant for designing a successful repurposed drug program with a viable business case in mind, which aspects are necessary to keep in mind in order to increase the odds of indeed finally making the drug available for patients in need thereof. Topics requiring attention are amongst others: (i) clinical trial design; (ii) pricing and reimbursement; (iii) registration requirements; (iv) key features making a drug repurposing program an attractive business model for investment; and (v) the benefits that patenting can provide for a drug repurposing program regarding staying in control when a pricing- and reimbursement scheme for example is established.

            In this presentation, this latter aspect, the role of patenting in drug repurposing programs, will be addressed. The embedded role that a well-designed patenting strategy can play in a drug repurposing program, will be highlighted. With special emphasize on the interconnections between IP protection and the other listed aspects. Some details will be shared on which aspects of a drug repurposing program are eligible for patent protection.

            Some examples of patentable subject matter commonly apparent while developing a repurposed drug are:

            (1) The known drug molecule, now used in the treatment of a new indication;

            (2) The known drug, now used in a new formulation for the new indication;

            (3) The known drug, now used at a different dose or in a different dosing regimen;

            (4) The known drug, now administered to the new patient group in a new manner.

            Content

            Author and article information

            Conference
            RExPO24 Conference
            REPO4EU
            7 May 2024
            Affiliations
            [1 ] NLO (NL);
            Author notes
            Author information
            https://orcid.org/0009-0000-9363-881X
            Article
            10.58647/REXPO.24000054.v1
            068b27f4-579d-4d62-a909-5db87eda9a81

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO24
            3
            Munich, Germany
            3-5 July 2024
            History
            : 6 May 2024
            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Pharmacology & Pharmaceutical medicine
            Drug repurposing,therapeutic application,clinical trial,pharmaceutical legislation,patenting

            Comments

            Comment on this article